For the quarter ended September 2026, Stryker (SYK Quick QuoteSYK - Free Report) reported revenue of $6.52 billion, up 7.6% over the same period last year. EPS came in at $3.52, compared to $3.19 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $6.58 billion, representing a surprise of -0.88%. The company delivered an EPS surprise of -1.12%, with the consensus EPS estimate being $3.56.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Stryker performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Sales by Geography- International: $1.57 billion versus the three-analyst average estimate of $1.73 billion. The reported number represents a year-over-year change of +5.7%.
• Net Sales by Geography- United States: $4.95 billion compared to the $4.85 billion average estimate based on three analysts. The reported number represents a change of +8.3% year over year.
• Net Sales by Geography- Orthopaedics: $2.86 billion versus the four-analyst average estimate of $2.88 billion. The reported number represents a year-over-year change of +26.7%.
• Net Sales by Business- MedSurg and Neurotechnology: $3.66 billion versus $3.7 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -3.7% change.
• Net Sales by Business- MedSurg and Neurotechnology- Medical: $1.08 billion versus the three-analyst average estimate of $1.13 billion. The reported number represents a year-over-year change of +9.8%.
• Net Sales by Geography- Orthopaedics- Knees: $635 million compared to the $647.78 million average estimate based on three analysts. The reported number represents a change of +1.1% year over year.
• Net Sales by Geography- Orthopaedics- Trauma and Extremities: $1.01 billion compared to the $1.09 billion average estimate based on three analysts. The reported number represents a change of +5.2% year over year.
• Net Sales by Business- MedSurg and Neurotechnology- Instruments: $996 million versus the three-analyst average estimate of $1.04 billion. The reported number represents a year-over-year change of +31.1%.
• Net Sales by Business- MedSurg and Neurotechnology- Endoscopy: $1.02 billion versus $1.02 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +14% change.
• Net sales- Orthopaedics - Ortho Tech: $754 million versus the three-analyst average estimate of $716.09 million.
• Net Sales by Business- MedSurg and Neurotechnology- Vascular: $566 million versus $499.87 million estimated by three analysts on average.
• Net Sales by Geography- Orthopaedics- Hips: $453 million versus $459.46 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -0.9% change.

View all Key Company Metrics for Stryker here>>>

Shares of Stryker have returned +10.4% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.